A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer

ABSTRACT: Interventions: Eribulin is administered intravenously at a dose of 1.4mg/m^2/day on Days 1 and 8, repeated every 21 days. Primary outcome(s): Confirmed objective response rate(ORR) by investigators’ assessment Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2646378 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR